LEV102 Topical Gel in Acquired Blepharoptosis
Study Details
Study Description
Brief Summary
Phase 1/2a, multicenter, randomized, vehicle-controlled, double-masked, multiple-dose, parallel-group study conducted in adult subjects with acquired blepharoptosis.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1/Phase 2 |
Detailed Description
This is a Phase 1/2a, multicenter, randomized, vehicle-controlled, double-masked, single-dose, parallel-group study conducted in adult subjects with acquired blepharoptosis. Subjects will receive a one-time application of randomized, double-masked IP. Approximately 30 subjects will be enrolled in this study. Eligible subjects will be randomized to 1 of the following 3 treatment groups in a 1:1:1 ratio and will receive a single dose of double-masked
IP externally on the upper eyelid of both eyes (OU):
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: LEV102 Topical Gel, 2.0%
|
Drug: LEV102 2.0%
Oxymetazoline ophthalmic gel
|
| Experimental: LEV102 Topical Gel, 1.0%
|
Drug: LEV102 1.0%
Oxymetazoline ophthalmic gel
|
| Placebo Comparator: Vehicle
|
Drug: Vehicle
Vehicle ophthalmic gel
|
Outcome Measures
Primary Outcome Measures
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) [Day 2-5]
Adverse events
Secondary Outcome Measures
- Upper eyelid height [Day 1]
Margin reflex distance 1
Eligibility Criteria
Criteria
Inclusion Criteria:
Subjects who meet all the following inclusion criteria will be eligible to participate in the study. Subjects must:
-
Be male or female subjects 25 years of age or older at the time of Screening (Visit 1)
-
Have complaints of aesthetically unacceptable upper eyelid position for both eyes making them desirous for elevation, or have complaints of superior visual field defects in both eyes that impact activities of daily living
-
Present with the following at Screening (Visit 1):
- At least one eye that meets both of the following criteria: i. Margin Reflex Distance 1 MRD1 ≤2 mm (no visible central pupillary light reflex defaults to 0) ii. Current corrected VA, using subject's own prescription eyeglasses, if applicable, in the qualifying eye(s) of +0.3 LogMAR (Logarithm of the Minimum Angle of Resolution) or better as assessed by ETDRS b. Demonstrate upper eyelid elevation ≥0.5 mm change from baseline in MRD1 in both eyes in response to a single drop of oxymetazoline 0.1% ophthalmic solution)to each eye at Screening
-
Women of Childbearing Potential must agree to use an approved method of birth control from the date they sign the informed consent form (ICF) until after the last study visit (Follow-Up Visit)
-
Be able to give informed consent and willing to comply with all study visits and examinations
Exclusion Criteria:
-
Have any other ocular pathology other than ptosis requiring treatment with topical prescription ophthalmic drops in either eye (e.g., glaucoma, dry eye)
-
Have narrow angles, glaucoma, intraocular pressure >23 mmHg or diagnosis of ocular hypertension, cup-to-disc ratio of >0.7, or history of any glaucoma eye surgery in either eye
-
Have any active ocular or peri-ocular infection; any history of recurrent or chronic infection or inflammation in either eye
-
Have a history of allergic reaction to the investigational drug or any of its components
-
Within 7 days of Screening (Visit 1), or anticipated use during the study, use of any systemic, intranasal, topical dermatologic, or ophthalmic α-adrenergic agonist (including brimonidine) or antagonist including nasal or ocular or oral decongestants including pseudoephedrine, oxymetazoline topical ophthalmic solution, oxymetazoline topical dermatologic cream
-
Subjects who are pregnant or breast-feeding
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Levation Pharma, Ltd.
Investigators
- Study Chair: Houman D Hemmati, MD PhD, Levation Pharma, Ltd.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- LEV102-CS01